Abstract
Recent findings in animals and in humans have shown that cannabinoid type 1 receptor antagonists are suitable to become the most promising validated class of drugs to tackle obesity and related disorders. This mini-review will provide a concise and updated revision of the state of art on this topic.
Keywords: Endocannabinoid, cannabinoid type 1 receptor, cannabinoid type 1 receptor antagonist, rimonabant, metabolic syndrome
Mini-Reviews in Medicinal Chemistry
Title: Cannabinoid Receptor Antagonists and the Metabolic Syndrome: Novel Promising Therapeutical Approaches
Volume: 7 Issue: 1
Author(s): C. Cervino, R. Pasquali and U. Pagotto
Affiliation:
Keywords: Endocannabinoid, cannabinoid type 1 receptor, cannabinoid type 1 receptor antagonist, rimonabant, metabolic syndrome
Abstract: Recent findings in animals and in humans have shown that cannabinoid type 1 receptor antagonists are suitable to become the most promising validated class of drugs to tackle obesity and related disorders. This mini-review will provide a concise and updated revision of the state of art on this topic.
Export Options
About this article
Cite this article as:
Cervino C., Pasquali R. and Pagotto U., Cannabinoid Receptor Antagonists and the Metabolic Syndrome: Novel Promising Therapeutical Approaches, Mini-Reviews in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/138955707779317812
DOI https://dx.doi.org/10.2174/138955707779317812 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Surgical Treatment of the Sleep Apnea Syndrome in the Twenty-First Century
Current Respiratory Medicine Reviews Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions
Current Pharmaceutical Design Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Craniofacial Anomalies: From Development to Molecular Pathogenesis
Current Molecular Medicine Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Progress in the Development of Melanocortin Receptor Selective Ligands
Current Pharmaceutical Design Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy
Current Medicinal Chemistry Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Molecular Mechanism of Aniline Induced Spleen Toxicity and Neuron Toxicity in Experimental Rat Exposure: A Review
Current Neuropharmacology Dipyridodiazepinone Analogs as Human Immunodeficiency Virus Type 1- Specific Non-Nucleoside Reverse Transcriptase Inhibitors: An Overview
Current Medicinal Chemistry Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design Therapeutic Potential of Cannabinoids in Schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued) Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry